Tradestie Institutional Equity Comparison Engine

FITZ vs PRME โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PRME Overall Edge

PRME Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Prime Medicine, Inc. Common Stock (PRME) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, FITZ trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus PRME at N/M Forward P/E and -2584.2% operating margin (+243.9% YoY). In options structure, FITZ sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PRME sits in SURGE (32nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
FITZ N/M vs PRME N/M Fwd P/E
Growth & Margin Winner PRME
Op Margin N/A vs -2584.2% ยท YoY N/A vs +243.9%
Momentum & Technical Winner PRME
1Y +0.5% vs +25.8% ยท 52W Pos 16% vs 47%
Options & Structure Winner PRME
UNCLASSIFIED (N/A IV) vs SURGE (32nd %ile IV)
FITZ US Equity
FITZ
Institutional Equity
$25.44
-2.15% 1D
Market Cap N/A
1M Return -1.74%
1Y Return +0.51%
Forward P/E N/M
Unified AI Score
57.6 / 100 HOLD
Tech 45.0 Fund 59.0 Flow 50.0 Mom 50.0
PRME NASDAQ
Prime Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.19
-1.87% 1D
Market Cap $949.9M
1M Return +20.75%
1Y Return +25.83%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 65.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FITZ +0.51% PRME +25.83% Spread: +22.73 pp (PRME Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
FITZ TTM Op. Margin: N/A PRME TTM Op. Margin: -2584.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FITZ vs PRME. Trailing 12-month operating profitability (FITZ N/A vs PRME -2584.2%) and valuation multiples (FITZ N/M vs PRME N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FITZ (2) vs PRME (6)
Institutional Metric FITZ PRME Criterion Row Winner
Market Capitalization Scale N/A $949.9M Larger Scale PRME
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +243.9% Higher Growth PRME
Operating Margin (TTM) Profitability N/A -2584.2% Higher Margin PRME
Net Profit Margin Profitability N/A 0.0% Higher Margin PRME
Return on Equity (ROE) Capital Efficiency N/A -207.2% Higher ROE PRME
52-Week Range Position Momentum 16% ($23โ€“$36) 47% ($3โ€“$6) Stronger Trend PRME
Beta / 30D Volatility Risk Regime 1.00ฮฒ ยท 27% Vol 2.45ฮฒ ยท 149% Vol Lower Realized Risk FITZ
Unified Institutional Score Composite Signal 57.6 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite FITZ

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FITZ vs PRME Buy Guide
FITZ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live FITZ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PRME SURGE
13d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 32nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live PRME Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FITZ nor PRME registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.